Vol 43 # 2 June 2011 - Kma.org.kw

98
The Knowledge of Teratogenicity in the Prevention of Congenital Anomalies
June 2011
88. Wilson RD. The use of folic acid for the prevention of
neural tube defects and other congenital anomalies.
SOGC Clinical Practice Guidelines. November 2003;
138.
89. Chodirker BN, Cadrin C, Davies GA, et al. Canadian
guidelines for prenatal diagnosis (Part 2-Techniques of
prenatal diagnosis). SOGC Clinical Practice Guidelines.
July 2001; 105.
90. Commission of the European Communities.
Communication from the Commission to the European
Parliament, the Council, the European Economic and
Social Committee and the Committee of the regions on
rare diseases: Europe’s challenges. (Accessed July 26,
2010 at http://ec.europa.eu/health/ph_threats/non_
com/docs/rare_com_en.pdf)
91. Dolk H. What is the “primary” prevention of congenital
anomalies Lancet 2009; 374:378.
92. Evaluation of the effectiveness of primary prevention
and assessment of the impact of developments in
prenatal screening. Project 2001/rd/10014 of the
DG Sanco rare diseases programme. Final activity
report for period December 2001 to December
2003. (Accessed July 26, 2010 at http://ec.europa.
eu/health/ph_threats/non_com/docs/rare_com_
en.pdf)
93. Early warning of teratogenic exposures and provision
of information regarding clusters or exposures or
risk factors of concern. Project 2001/rd/10014 of the
DG Sanco rare diseases programme. Final activity
report for period December 2001 to December
2003. (Accessed July 26, 2010 at http://ec.europa.
eu/health/ph_threats/non_com/docs/rare_com_
en.pdf)